

TAIPEI

Exhibition Area At MEDICA 2025

臺北市生技產業
國際商機拓展計畫成果專刊

Taipei Biotech Global Market Expansion Program —
Highlights & Achievements

MEDICA
Hall 16, C13-3~8



計畫緣起及目標

Introduction

2025 生技海外市場開發實戰工作坊

2025 Pre-Exhibition Workshop on Global Market Development for Biotechnology

臺北生醫躍國際!北市6家企業閃耀MEDICA 2025!

Taipei Biotech Goes Global: Six Taipei Companies Shine at MEDICA 2025

2025 MEDICA 「臺北展區」

Taipei Exhibition Area at MEDICA 2025

起元生物科技股份有限公司

Origin Biotechnology Co., Ltd.

中聯環境生技股份有限公司

Union Biomedical Corporation

蓋德科技股份有限公司

GuiderCare Limited

豪紳纖維科技股份有限公司

Asiatic Fiber Corporation

神經元科技股份有限公司


Neurobit Technologies Co., Ltd.

博唯弘展生技股份有限公司

Proview-MBD Biotech Co., Ltd.

結語

Conclusion



計畫緣起及目標



▲ 臺北展區6家參展廠商於展區前合影 Group photo

為行銷臺北市生技產業發展特色、優質投資環境及「生技之都」形象，協助臺北市生技產業國際鏈結、全球市場拓展，規劃邀集本市生技廠商共同組團參與國際生技展會，透過海外國際展會渠道，加速本市生技廠商開拓國際市場版圖，引領生技廠商國際接軌，積極促成產業商機交流合作。

2024年臺北市政府產業發展局首次辦理2024 MEDICA「臺北展區」，透過補助現場展示攤位及大會媒體登錄資格，協助6家北市績優生技企業以最直接的協助鼓勵廠商走向國際、拓展商機，4天展會期間共達成266場次展期洽商，6家國內外生技媒體報導，促成廠商品牌曝光、產品銷售、技術移轉、共同研發...等商機交流與合作。另一方面，運用海外國際展會渠道，向國際宣傳與介紹臺北市的完善產業發展環境、生技產業發展優勢及未來生技發展藍圖。

2025年持續鎖定全球規模最大的專業醫療器材貿易展-德國杜塞道夫國際醫療器材展(MEDICA)為臺北館參展標的，進行籌展相關規劃。

德國杜塞道夫國際醫療器材展(MEDICA)，2024年共計有來自全球5,800家專業醫療器材廠商參展，涵蓋實驗室/體外診斷、醫療耗材、醫用IT解決方案、物理治療/骨科、醫療科技/電子醫材等五大醫材及技術應用領域，涵蓋整個醫療技術價值鏈而成為全球獨一無二的展覽會，吸引全球來自165個國家的約80,000名專業觀眾前來參觀，為醫療器材廠商鏈結全球商機最佳國際展會平台。



Introduction

2025 TAIPEI • Where Biotech Innovation Meets the World

Hall 16, Booth C013-3~8
(Taiwan Pavilion)



MEDICA
Düsseldorf,
Germany
17–20 Nov.
2025



▲ 臺北展區網站廣宣橫幅 Banner


To showcase Taipei's thriving biotechnology sector, its attractive investment environment, and its vision as the "City of Biotech," the Taipei City Government actively supports local biotech companies in building global connections and expanding into international markets. By organizing joint delegations to major global biotechnology exhibitions, Taipei empowers its biotech enterprises to accelerate international outreach, explore new market opportunities, and foster cross-border partnerships and collaborations.

In 2024, the Taipei City Government's Department of Economic Development launched the first-ever Taipei Exhibition Area at MEDICA 2024 to promote the city's leading biotech innovators on the global stage. Through subsidies for exhibition booths and official media registration, the initiative enabled six outstanding Taipei-based biotech companies to showcase their cutting-edge products and connect directly with international partners.

Over the four-day exhibition, the Taipei Pavilion facilitated 266 business meetings and was featured by six domestic and international biotech media outlets, generating substantial global exposure and fostering opportunities for brand promotion, product sales, technology transfer, and joint R&D collaborations. At the same time, participation in this premier event highlighted Taipei's robust industrial ecosystem, innovation capacity, and long-term development vision, presenting Taipei as a dynamic force in the global biomedical landscape.

Building on the success of 2024, the Taipei City Government will continue its participation at MEDICA 2025—the world's largest trade fair for medical technology—by once again organizing the Taipei Pavilion. Preparations are already underway to ensure a strong presence that showcases Taipei's innovation strengths and its pivotal role in the global biomedical supply chain.

MEDICA, held annually in Düsseldorf, Germany, is the world's leading exhibition for medical devices and technologies. In 2024, the event featured over 5,800 exhibitors from across the globe, covering five key sectors—laboratory and in-vitro diagnostics, medical consumables, medical IT and digital solutions, physiotherapy and orthopedics, and medical technology and electronics—representing the entire value chain of medical innovation. With approximately 80,000 professional visitors from 165 countries, MEDICA serves as the premier global platform connecting healthcare innovators, suppliers, and buyers across the industry.



2025 生技海外市場開發實戰工作坊



▲ 2025生技海外市場開發實戰工作坊主視覺 Workshop key visual

隨著生技產業走向國際，參展廠商在國際展會中面臨越來越多元的挑戰。為了協助臺北展區參展廠商提升其在展會期間的成果與效益，我們規劃辦理此展前輔導工作坊。工作坊的設計旨在幫助參展人員(或該公司商業拓展部門人員)提升其在國際舞台上的品牌溝通、商業開發與商機轉化的綜合能力，將參展投資精準轉化為實質的商業成果與長期的合作夥伴關係。

根據參展商產品分類、領域及展會的特性，為期兩天的工作坊以實戰為導向，系統性地涵蓋從展前策略佈局到展後成果擴大的完整流程。本屆展前輔導工作坊的舉辦，不僅是對參展廠商的專業實務演練，也是生技產業內的交流合作互相學習的機會。透過整體的課程設計，與會者將能夠在實踐中學習，提高商洽溝通技巧與能力，進而提升參展效益。



▲ 工作坊講師：(上)楊富翔 講師、(下)朱裕誠 講師
Workshop instructors: (Upper) West Yang, (Lower) Chester Chu

2025 Pre-Exhibition Workshop on Global Market Development for Biotechnology


As Taipei's biotechnology industry continues to expand globally, exhibitors are encountering increasingly diverse challenges at international trade shows. To help participating companies in the Taipei Pavilion maximize their exhibition performance and outcomes, a Pre-Exhibition Workshop was organized. The workshop aimed to strengthen participants'—particularly business development teams'—skills in brand communication, business negotiation, and opportunity conversion on the global stage, ensuring that their exhibition investment translates into tangible business results and long-term partnerships.

Tailored to the exhibitors' product categories, industry fields, and the specific nature of the event, the two-day program adopted a hands-on, practice-oriented approach, systematically covering the entire process from pre-show strategic planning to post-show outcome amplification. Beyond professional training, the workshop also served as a valuable platform for knowledge exchange and collaboration within Taipei's biotech community. Through this comprehensive program, participants enhanced their practical skills in business communication and engagement, ultimately improving their overall exhibition effectiveness.



▲ 工作坊學員透過經驗分享、提問、討論增進國際商務拓展能力
Participants strengthen international business development skills
through interactive discussion

臺北生醫躍國際!北市6家企業閃耀MEDICA 2025!



▲北市府率6家生技企業赴德參加MEDICA2025 Group photo

臺北市政府產業局攜手本市6家優秀生技企業-神經元科技、起元生技、中聯環境生技、博唯弘展生技、蓋德科技及豪紳纖維科技，共組「臺北展區」參加全球最具指標性的「德國杜塞道夫國際醫療器材展(MEDICA 2025)」，展現臺北生醫產業的創新實力！

產業局表示，2025德國醫材展臺北展區企業，多元與優異的產品技術，吸引來自英國、荷蘭、巴西、美國、葡萄牙、義大利...等多國通路/代理商、CRO、投資者參觀洽商，締造媒合洽談逾400場，其中，博唯弘展與蓋德科技於台灣館產品發表會出色的表現，成功吸引國際目光，展現拓展全球市場的實力與企圖心！

2025德國醫材展臺北展區參展企業，展現生醫產業的創新實力與多元特色，其中神經元科技展出已獲FDA認證的NeuroSwift® Pro神經系統檢測系統，運用AI技術協助早期腦部疾病診斷，吸引多家歐洲醫學中心洽詢合作。起元生技以取得CE-IVD認證與多項核心專利的快速基因檢測套組登場，展現可助力新生兒及高風險族群多項遺傳疾病優勢。中聯環境生技呈現先進的內視鏡全自動低溫滅菌與清洗消毒整合方案，可有效簡化醫院作業流程並提升感染控制效率。蓋德科技以具備醫療級物聯網平台資格的300B醫療穿戴系統與900Q 4G智慧手錶，展現智慧醫材的創新量能。豪紳纖維科技的AFC C-R15手術刷手衣符合歐洲嚴格標準，兼具高溫滅菌與耐洗特性，體現永續醫療紡織創新力。博唯弘展發表具多國專利的防沾黏噴霧Thergi Spray及艾達貝爾凝膠，獲得洽商者高度評價！

產業局指出，生技產業正處於全球版圖拓展的關鍵時刻，臺北市政府將與生技企業併肩前行，持續協助企業鏈結全球資源、開啟商機渠道，讓「生技臺北」品牌從臺北出發，耀眼全球！

Taipei Biotech Goes Global: Six Taipei Companies Shine at MEDICA 2025

The Taipei City Government Department of Economic Development has joined forces with six leading Taipei-based biotech companies—Neurobit Technologies, Origin Biotechnology, Union Biomedical, PROVIEW-MBD Biotech, GuiderCare, Asiatic Fiber—to form the “Taipei Exhibition Area” at the world’s largest medical trade fair, MEDICA 2025 in Düsseldorf, Germany. The collective showcase highlighted Taipei’s growing strength in biomedical innovation.

According to the Department, the Taipei Exhibition Area at this year’s exhibition attracted strong international interest, drawing distributors, CROs and investors from the United Kingdom, the Netherlands, Brazil, the United States, Portugal and Italy, among others. More than 400 business matchmaking meetings were held during the event. In particular, PROVIEW-MBD Biotech and GuiderCare stood out at the Taiwan Pavilion product launch sessions, capturing significant international attention and demonstrating strong momentum for global market expansion.

The six participating companies presented a diverse range of cutting-edge medical technologies. Neurobit Technologies showcased its NeuroSwift® Pro neurological assessment system, which has received approval from the U.S. Food and Drug Administration and applies AI technology for early detection of brain disorders, drawing enquiries from multiple European medical centers. Origin Biotechnology introduced its rapid genetic testing kits, certified with CE-IVD and protected by multiple core patents, offering efficient solutions for newborns and high-risk populations. Union Biomedical presented an advanced automated low-temperature endoscope sterilization and disinfection system that streamlines hospital workflows and enhances infection control. GuiderCare displayed its medical-grade IoT-certified 300B wearable medical system alongside the 900Q 4G smart medical watch, highlighting innovation in smart healthcare devices. Asiatic Fiber’s C-R15 surgical scrub suit met stringent European standards, combining high-temperature sterilization resistance with durability, reflecting advances in sustainable medical textiles. PROVIEW-MBD Biotech also introduced its multi-patented ThergiSpray anti-adhesion spray and AtamaBarrier anti-adhesion gel, both of which received enthusiastic feedback from international buyers.

The Department emphasized that the global expansion of the biotech industry has reached a critical stage. The Taipei City Government will continue to work closely with local biotech enterprises to connect them with global resources and commercial opportunities, ensuring that the “Bio@Taipei” brand continues to grow from Taipei to the world stage.




▲臺北展區廠商與洽商對象互動 (左) 中聯環境生技 (中) 神經元科技 (右) 起元生技
 Exhibitors interact with business partners: (Left) Union Biomedical (Center) Neurobit Technologies (Right) Origin Biotechnology




▲臺北展區廠商與洽商對象互動 (左) 蓋德科技 (中) 豪紳纖維 (右) 博唯弘展
 Exhibitors interact with business partners: (Left) GuiderCare (Center) Asiatic Fiber (Right) Proview-MBD

2025 MEDICA「臺北展區」

Taipei Exhibition Area at MEDICA 2025



▲臺北展區位於杜塞道夫展覽貿易中心16館C13-3~8
Taipei Exhibition Area located at Hall 16, Booth C13-3~8



臺北展區廠商

Exhibitors in Taipei Exhibition Area

Booth

C13-3



起元生物科技股份有限公司
Origin Biotechnology Co., Ltd.

C13-4



中聯環境生技股份有限公司
Union Biomedical Corporation

C13-5



蓋德科技股份有限公司
GuiderCare Limited

C13-6



豪紳纖維科技股份有限公司
Asiatic Fiber Corporation

C13-7



神經元科技股份有限公司
Neurobit Technologies Co., Ltd.

C13-8



博唯弘展生技股份有限公司
Proview-MBD Biotech Co., Ltd.



▲ 起元產品介紹展板 Posters of Origin Biotechnology

起元生技為一家具備自主研發實力的創新生技公司，專注於分子診斷領域。我們以「快速、精準的體外診斷試劑」為核心發展策略，致力於解決臨床尚未被滿足的關鍵需求。公司使命聚焦於婦女疾病、兒童疾病及遺傳性疾病之預防、篩檢與診斷。

近年來，在遺傳疾病檢測方面取得重大突破，成功開發完整的基因疾病檢測套組與全方位片段分析解決方案，提供可有效取代現行 CNV 金標準的先進替代方案。產品線涵蓋 X 脆性症(FXS)、脊髓性肌肉萎縮症(SMA)及地中海型貧血(Thalassemia)等檢測項目，於檢測規格與覆蓋率上均展現卓越表現。此外，更推出全球首款且唯一的川崎氏症(Kawasaki Disease)診斷試劑，填補兒科臨床診斷上急迫且長期未被滿足的醫療需求。

Origin is an innovative biotechnology company based on autonomous research and development to the field of molecular diagnostics. Our business strategy aims to develop rapid, accurate IVD kit to fulfill unresolved clinical demands. Our mission focus on prevention, screening, and diagnose of gynecological, pediatric, and genetic disease. We have recently made significant breakthroughs in developing a comprehensive panel for genetic disease testing and a full-scope fragment analysis solution, offering an advanced alternative to the current CNV gold standard. Our product portfolio demonstrates outstanding performance in Fxs, SMA, and Thalassemia testing in both specifications and coverage. Moreover, we offer the world's first and only IVD assay for Kawasaki Disease, addressing an urgent unmet need in pediatric diagnostics.



網站
Website

聯絡人 Willie Chen
Contact yuwei@oribio.com.tw

業務領域

Major Fields

● 醫療器材研發	● Medical Device development
● 體外診斷 (IVD)	● In Vitro Diagnostics (IVD)
● 基因檢測	● Genetic Testing
● 攜因者檢測／新生兒篩檢	● Carrier/Newborn Screening

合作意向

Business Interests

技術授權(引進/授出)、通路經銷合作、OEM／ODM 代工合作、共同

開發合作、產學合作進行 IVD 臨床驗證。

Licensing (In & Out), Distribution Partnerships, OEM / ODM

Collaboration, Joint Development, Academic/Industry

Collaboration for IVD Validation.

產品介紹

Product Description

PCR-CE SMN／DMD 試劑組

本公司神經肌肉疾病檢測套組整合脊髓性肌肉萎縮症(SMA)與裘馨氏肌失養症(DMD)之檢測，採用螢光PCR結合毛細管電泳(PCR-CE)技術平台建構而成。SMA檢測可於3小時內同時定量SMN1與SMN2第7/8外顯子拷貝數，支援精準基因型判讀與臨床用藥決策。

DMD檢測則可完整分析DMD基因全部79個外顯因子，有效偵測基因缺失或重複變異，全面涵蓋裘馨氏肌肉失養症(Duchenne)與貝克型肌肉萎縮症(Becker)之檢測需求。本套組具備高靈敏度、可全自動化操作，並可完整取代傳統MLPA技術，特別適用於攜因者篩檢、新生兒篩檢及神經肌肉疾病早期診斷，為臨床提供快速且高準確度的分子診斷解決方案。

PCR-CE SMN/DMD kit

Our neuromuscular disease panel integrates SMA and DMD testing using a fluorescence PCR-capillary electrophoresis (PCR-CE) platform. The SMA assay quantifies SMN1 and SMN2 exon 7/8 copy numbers within 3 hours, supporting accurate genotype classification and clinical decision-making. The DMD assay evaluates all 79 exons of the DMD gene to detect deletions or duplications, enabling comprehensive coverage for Duchenne and Becker muscular dystrophy. Both assays offer high sensitivity, full automation compatibility, and complete replacement of MLPA. Ideal for carrier screening, newborn testing, and early diagnosis of neuromuscular disorders.



▲ 拍攝參展影片介紹產品解決方案
Filming a product solution introduction video

PCR-CE FMR1及地中海型貧血 檢測試劑組

本檢測套組整合X脆性症(Fragile X Syndrome)與地中海型貧血(Thalassemia)之分子診斷，採用螢光PCR結合毛細管電泳(PCR-CE)單一整合平台進行分析。FMR1檢測可精準定量CGG重複序列數目，並可穩定偵測超過200次重複之全突變(Full Mutation)，具備優異的擴增穩定度與結果重現性。

地中海型貧血檢測可於單一反應管(single-tube)流程中，同時鑑別超過8種 α -型地中海型貧血缺失型變異、3種 α 點突變、17個 β -型地中海型貧血熱點突變，並涵蓋大型缺失變異，提供高度完整的基因變異檢測能力。

本套組具備高通量、高準確度檢測效能，整體檢測時間僅需4-5.5小時，可同時支援攜因者篩檢與臨床確診檢測。相較於傳統MLPA與次世代定序(TGS)平台，本產品提供具高度效率與臨床實用性的替代方案，為遺傳疾病檢測提供快速、精準且具成本效益的解決方案。

PCR-CE FMR1 & Thalassemia kit

This panel combines Fragile X Syndrome and thalassemia testing into a unified PCR-CE solution. The FMR1 assay delivers accurate quantification of CGG repeats—including full mutations exceeding 200 repeats—with exceptional amplification stability and result reproducibility. The thalassemia assay distinguishes over eight α -thalassemia deletions, three α -point mutations, 17 β -thalassemia hotspots, and large deletions in a single-tube workflow. Results are available in 4–5.5 hours with high throughput and diagnostic precision. This comprehensive panel supports both carrier screening and confirmatory diagnostics, offering a powerful alternative to MLPA and TGS platforms.



▲ 起元團隊於攤位前合照 Origin Team



▲ 兩組客戶同時進行洽商 Simultaneous business talks with two client groups



▲ 中聯環境生技產品介紹展板 Posters of Union Biomedical

成立於 1988 年，專注於消毒、滅菌、皮膚與傷口照護及醫療器材等領域，擁有多項專利產品，長期深耕醫療感染控制與臨床照護應用。

Established since 1988, with patented products covers disinfection, sterilization, for skin and wound treatment as well as medical devices.



▲ 中聯環境生技丁力行博士 Dr. Lambert Ding



業務領域

Major Fields

- 醫療產品之設計、研發與製造
- Medical products design, research and manufacturing.
- 提供各類客戶全方位之滅菌應用解決方案
- Sterilization applications for all clients.

合作意向

Business Interests

誠徵全球各國銷售代理商與業務代表，並尋求具策略性之投資合作夥伴。

Looking for sales agents and representatives in countries around the world, as well as strategic investor partners.

產品介紹

Product Description

創新內視鏡全自動清洗消毒滅菌系統

【創新亮點】

UNIONSCOPE為全球首創之全自動內視鏡清洗、消毒與低溫滅菌一體化設備，整合「清洗、消毒、滅菌」三大功能於單一系統，提供一鍵式全自動操作流程，無須人工清洗前處理，大幅節省作業時間及成本費用，並降低人為操作品質不佳的風險。

本設備為目前全球速度最快的內視鏡低溫滅菌創新技術方案，可於30分鐘內自動同步完成2支內視鏡之清洗、消毒與滅菌作業，有效消除交叉感染風險，並且可以將現行國際內視鏡高級消毒標準提升至完全滅菌的創新技術產品，符合內視鏡感染管制與滅菌相關法規標準，可協助全球醫療院所提升侵入式醫療器材滅菌作業效率，保護病人安全。

Innovative endoscopy automatic washer and sterilizer

【Innovation Highlights】

UNIONSCOPE is the world's first fully automated endoscope reprocessing system that integrates cleaning, disinfection, and low-temperature sterilization into a single device. It enables a true one-touch, fully automated workflow without the need for manual pre-cleaning, significantly reducing labor time, operational costs, and the risks associated with inconsistent manual handling.

This system currently represents the fastest low-temperature sterilization solution for endoscopes worldwide. It can automatically clean, disinfect, and sterilize two endoscopes simultaneously within 30 minutes, effectively eliminating cross-infection risks. By elevating the current global standards from high-level disinfection to full sterilization, UNIONSCOPE provides an innovative solution that meets international endoscope infection-control and sterilization regulations. It empowers healthcare institutions worldwide to enhance the efficiency of reprocessing invasive medical instruments while strengthening patient safety.



▲ 丁博士向參觀者演示產品操作流程
Dr. Ding demonstrates the product to visitors

Union 液體繃帶

Union Liquid Bandage 本產品可直接噴塗於皮膚傷口或燒燙傷患部，於傷口表面形成保護膜，有效促進傷口癒合、降低感染風險，提供快速且便利之傷口防護與照護解決方案。

1. 廣泛應用於全球戰地與緊急醫療救護之傷口處理，為外傷患者之高效傷口照護解決方案。
2. 適用於各類型傷口，可有效加速傷口癒合、提升修復效率。
3. 產品具備安全、無毒、無刺激性之特性，為可取代酒精與碘酒之新世代傷口處理產品，提供更溫和且高效的傷口護理選擇。

Union Liquid Bandage

Union Liquid Bandage: This product can be directly sprayed on skin wounds or burns to enhance healing.

1. The best wound treatment product for injured patients during global wars.
2. Applicable to all kinds of wounds and accelerate healing.
3. Safe, non-toxic, non-irritating, the best wound treatment product to replace alcohol and iodine.



▲ 丁博士向參觀者介紹產品解決方案
Introducing product solutions



▲ 中聯環境生技團隊
於攤位前合照
Union Biomedical Team



- AI Digital Health Platform
- Homecare Solutions
- Remote Patient Monitoring

A digital Health system for real-time monitoring and management of patients in hospitals and at home.



▲ 蓋德產品介紹展板 Posters of GuiderCare

300B & 900E



▲ 蓋德團隊於攤位合照 GuiderCare Team

蓋德科技成立於 2008 年，為亞洲最成熟的數位健康平台公司之一。解決方案涵蓋醫療級穿戴式 IoT 系統、資料與使用者管理系統、服務型應用程式(App)，以及資料分析與生成式 AI 系統等，提供完整的一站式智慧醫療服務平台。目前客戶涵蓋醫院、診所、長照機構、健康檢查中心、企業與工廠、交通運輸業等多元領域，廣泛應用於臨床照護、健康管理與企業員工健康服務。蓋德科技預計於 2025 年底於美國那斯達克(Nasdaq)掛牌上市，邁向國際資本市場，拓展全球數位醫療版圖。

GuiderCare was founded in 2008 and is one of the most mature digital healthcare platform companies in Asia. Its solutions include medical wearable IoT systems, data and user management systems, service application apps, data and generative AI systems, etc. Our customers include hospitals, clinics, nursing homes, health check-up centers, enterprises and factories, transportation companies and other fields. GuiderCare is expected to be listed on the Nasdaq in the United States by the end of 2025.



網站
Website

聯絡人 Ricky Hsu
Contact ricky@guidercare.com

業務領域

Major Fields

- 醫院病患安全輔助系統
- 高齡照護監測系統（長照監測系統）
- Hospital patient safety assistance system.
- Elderly care monitoring system.

合作意向

Business Interests

原廠設計製造、原廠委託製造、一站式整合交付、通路經營/通路合作。

ODM, OEM, Turn-Key, Channel Biz.

產品介紹


Product Description

300B 醫療級穿戴式 IoT 系統

300B 醫療級穿戴式 IoT 系統整合穿戴式終端裝置、藍牙閘道器（Bluetooth Gateway）、定位節點、後台管理系統及服務型應用程式（App），可於醫療院所以大規模方式連結與管理病患，即時進行生理數據監測。本系統具備 SOS 緊急求助、一鍵通報、即時定位與行動軌跡追蹤、醫療服務即時連線等功能，可有效建構病患安全防護機制、提升護理照護效率、支援遠距醫療應用，並結合 AI 發展個人化智慧醫療與照護服務，協助醫院全面升級智慧醫療與病患照護品質。

300B Medical Wearable IoT System

The 300B medical wearable IoT system includes terminals, Bluetooth Gateway, positioning points, background management systems and service apps. It can connect patients on a large scale in hospitals, monitor physiological data in real time, and has a SOS button, positioning and trajectory monitoring, and real-time connection to medical services, building patient safety, nursing efficiency, telemedicine and AI personalized medical care and care for hospitals.



▲ 蓋德攤位參觀、詢問人潮衆多
Strong visitor turnout at GuiderCare's booth

900Q 醫療級 4G 穿戴式 IoT 系統

900Q 智慧手錶具備先進之生理數據即時監測與異常預警功能，內建 Qualcomm 4G 通訊系統，提供即時通話、定位追蹤與緊急求助(SOS)等完整通訊與安全機制。

本系統可廣泛應用於心血管疾病患者監測、駕駛人行為監控及高風險工作場域安全監測等情境，並搭配大規模即時後台管理系統、即時應用程式(App)，以及 AI 數據分析與應用系統，協助醫療與企業用戶建構即時監控、智慧管理與預測式照護之整合型穿戴式醫療應用平台。

900Q Medical 4G Wearable IoT System

900Q Smartwatch has advanced physiological data real-time monitoring and warning capabilities, built-in Qualcomm 4G system, and has real-time call, positioning, and emergency functions. It can be used for cardiovascular disease patient monitoring, driver monitoring, and dangerous workplace monitoring, and has real-time large-scale management background, real-time application APP, and AI data analysis and application system.



▲ 蓋德入選台灣館趨勢發表會 GuiderCare selected for Taiwan Pavilion Trend Presentation



▲ 蓋德向參觀者介紹產品解決方案 Introducing product solutions



▲ 豪紳纖維產品介紹展板 Posters of Asiatic Fiber

豪紳纖維科技 (Asiatic Fiber Corporation, AFC) 為立基於台灣的智慧機能紡織先驅，專注於醫療用、無塵室用及穿戴式健康應用之高階機能性紡織品。憑藉超過 40 年的技術研發與創新經驗，AFC 將遠紅外線放射、除臭、靜電防護 (ESD) 及抗菌等核心技術整合於高效能布料中，廣泛應用於可重複使用之醫療與防護性紡織產品。

AFC 致力於重新定義醫療用紡織品的價值，不僅止於取代一次性產品，更透過先進布料工程技術，在舒適性、防護力與永續性三大面向全面升級。今年重點推出的新世代手術服布料，兼具國際認證之高等級防護、優異透氣性及長效耐用性，為臨床人員打造安心且舒適的工作環境。

從手術服、醫療防護服到健康機能服飾，AFC 持續提供兼具智慧化與環保永續的高機能紡織解決方案，協助醫療產業邁向更高效率、更舒適且更永續的未來。

Asiatic Fiber Corporation (AFC) is a Taiwan-based pioneer in smart functional textiles for medical, cleanroom, and wearable health applications. With over 40 years of innovation, AFC integrates far-infrared emission, odor control, ESD protection, and antibacterial technologies into high-performance fabrics for reusable healthcare and protective wear.



▲ 豪紳纖維 汪專員 Mrs. Wang from Asiatic Fiber



網站
Website

聯絡人
Ellen Wang
Contact ellen.wang@asiatic.com.tw

AFC is dedicated to redefining medical textiles—not just replacing disposable products, but delivering next-level comfort, protection, and sustainability through advanced fabric engineering. This year, we highlight a new-generation scrub suit fabric featuring certified high-level protection, exceptional breathability, and long-term durability.

From surgical attire to health-functional apparel, AFC offers smart, eco-conscious textile solutions that help the healthcare industry move toward a more efficient, comfortable, and sustainable future.

業務領域

Major Fields

機能性紡織品應用：

- 醫療用服飾與手術用紡織品
- 穿戴式健康與保健應用解決方案
- 無塵室及靜電防護 (ESD) 專用服飾
- 適用於高法規管制環境之永續可重複使用防護服飾

Functional textiles for:

- Medical wear & surgical textiles
- Wearable health & wellness solutions
- Cleanroom & ESD protection apparel
- Sustainable reusable garments for high-regulated environments

合作意向

Business Interests

- 自有品牌：AFC iQmax、AFC EASY CARE、AFC WELLNESS、AFC CIRCULAR
- 原廠設計製造服務
- OBM：AFC iQmax, AFC EASY CARE, AFC WELLNESS, AFC CIRCULAR
- ODM



▲ 與外國買主洽談商務合作 Business meetings with international buyers

產品介紹

Product Description

AFC® C-R15 手術服布料

因應醫療院所邁向永續化與高機能醫療服飾的趨勢，AFC推出全新 Air Scrub Suit-C-R15手術服專用機能布料，結合 EN 13795-2 高防護等級標準、極致透氣性與卓越導濕排汗性能(RET 2.54)，重新定義醫療服飾的舒適與防護境界。即使於長時間、高強度工作班別中，亦能迅速排除汗水，保持乾爽舒適，同時兼具如運動服般柔軟親膚的穿著觸感。



C-R15採用導電紗設計，提供優異的靜電抑制效果，並可承受高溫滅菌與多次反覆清洗，具備高度耐用性。其超快速乾燥特性可有效縮短烘乾時間、降低能源消耗，實質支持醫療院所的永續與節能目標。

「我們希望醫護人員不僅感受到完善的防護，更能同時享有舒適、自信且兼顧永續理念的醫療服飾。」— AFC

AFC® C-R15 Scrub Suit Fabric

As hospitals move toward sustainable and high-performance apparel, AFC introduces the Air Scrub Suit-C-R15—a breakthrough fabric designed to redefine medical apparel by combining EN13795-2 High Performance protection, extreme breathability, and outstanding moisture management (RET 2.54). Even during long, high-intensity shifts, it quickly wicks away sweat to keep healthcare professionals dry and comfortable, while maintaining a soft, activewear-like feel. Engineered with conductive yarn for superior static control, Air Scrub Suit-C-R15 withstands high-temperature sterilization and repeated washing, and its ultra-fast drying reduces dryer time and energy use, supporting hospitals' sustainability goals.

“We want healthcare professionals to feel protected, comfortable, and confident knowing their scrubs are designed with sustainability in mind.” — AFC



▲ 向參觀者介紹產品解決方案 Introducing product solutions

The image displays two promotional posters for Neurobit Technologies. The left poster is for 'NeuroSwift Pro', featuring a woman in a white coat and a man in a white coat examining her. The right poster is for 'NeuroSwift® Pro', showing a person wearing a head-mounted device with a brain visualization. Both posters include QR codes and social media links.

NeuroSwift Pro

Smarter brain health decisions, powered by intelligent eye-tracking across vertigo, balance, and neurological care

Intelligent Neurofunctional Screening for Brain Health

- ✓ All-in-One Platform
- ✓ AI-Guided Insights
- ✓ Instant Reporting
- ✓ FDA & TFDA Cleared Medical Device

VISIT US TODAY!

NeuroSwift® Pro

Professional Eye Movement Analysis for Comprehensive Neurological and Balance System Assessment

FDA & TFDA Cleared Medical Device

Video Frenzel, Positional, Oculomotor, AIVertigo

Advanced Eye Tracking Technology, Reliable Data and Reporting, Enhanced Comfort and Ergonomics, Superior Imaging Capabilities, Clinical Benefits and Diagnostic Capabilities

▲ 神經元產品介紹展板 Posters of Neurobit Technologies

神經元科技是一家以視覺生理訊號為核心的智慧醫療創新公司，致力於建構新世代智慧健康照護平台。透過整合眼球運動數據、光學量測技術與 AI 分析演算法，開發多元解決方案，應用於臨床決策支援、健康風險預測及以病人為核心的照護服務。

技術涵蓋神經系統與前庭功能診斷、兒童近視風險追蹤等多項醫療應用，並已取得多國醫療器材認證，具備正式臨床使用資格。產品深獲神經科、眼科、耳鼻喉科、家庭醫學科及預防醫學領域等專科醫師信賴，廣泛導入臨床實務。神經元科技以平台化(Platform-first)策略結合深厚的跨領域專業實力，持續重新定義視覺訊號於醫療應用中的價值，推動更智慧、更快速且具高度規模化的醫療服務模式。

Neurobit is a biomedical innovation company building intelligent healthcare platforms based on visual physiological signals. By integrating eye movement data, optical measurements, and AI analytics, we develop solutions for clinical decision support, health risk prediction, and patient-centered care.

Our technologies range from neurological and vestibular diagnostics to myopia risk tracking in children and are certified for medical use across multiple regions. Our products are trusted by specialists in neurology, ophthalmology, ENT, family medicine, and preventive healthcare. With a platform-first approach and deep interdisciplinary expertise, Neurobit is redefining how visual signals drive smarter, faster, and more scalable healthcare.

業務領域 Major Fields

- 數位健康/數位醫療、AI 臨床決策支援系統、神經系統與前庭功能診斷
- Digital Health, AI-based Clinical Decision Support, Neurological and Vestibular Diagnostics

合作意向 Business Interests

誠摯邀請您與我們攜手拓展 AI 眼動追蹤診斷於全球市場的應用版圖，並共同開發整合式腦健康解決方案。
Partner with us to expand AI-powered eye-tracking diagnostics worldwide and co-create integrated brain health solutions.



▲ 神經元團隊於攤位合照 Neurobit Team



▲ NeuroSwift® Pro展品照片 Photo of NeuroSwift® Pro

產品介紹 Product Description

NeuroSwift® Pro


NeuroSwift® Pro為一套以 AI 為核心的腦部相關疾病臨床決策支援系統，透過即時擷取與分析眼球運動、前庭訊號及瞳孔反應等視覺生理數據，提供客觀量化之生物指標，協助臨床醫師精準辨識各類神經系統疾病，包括帕金森氏症、中樞性眩暈及腦震盪後症候群等。系統整合多項先進 AI 模組，包含自動眼震偵測、注視穩定度分析與瞳孔追蹤技術，可有效偵測傳統例行檢查中易被忽略之細微異常變化，大幅提升神經與前庭功能評估之靈敏度與準確性。

NeuroSwift® Pro可自動產出結構化檢測報告與視覺化分析圖表，支援臨床診斷判斷與後續追蹤監測；並可進一步整合導引式評估平台 AIVertigo，導入症狀導向分流與檢測建議機制。此整合應用可有效提升診斷正確性、優化臨床工作流程，並強化神經內科、耳鼻喉科與一般門診之臨床決策效率。

NeuroSwift® Pro

NeuroSwift® Pro is an AI-powered clinical decision support system for brain-related disorders. It captures and analyzes eye movement, vestibular signals, and pupillary responses to provide objective biomarkers essential for identifying neurological conditions such as Parkinson's disease, central vertigo, and post-concussive syndrome. The system integrates advanced AI modules including automatic nystagmus detection, gaze fixation analysis, and pupil tracking. These tools enable clinicians to detect subtle abnormalities that are often missed during routine examinations.

NeuroSwift® Pro generates structured reports and visual analytics that support diagnostic reasoning and follow-up monitoring. When combined with AIVertigo, a guided evaluation platform, the system can incorporate symptom-based triage and testing recommendations. This integration improves diagnostic accuracy, streamlines clinical workflows, and enhances decision-making in neurology, otolaryngology, and general practice settings.



▲ 參觀者實際體驗產品功能
Experiencing product features



▲ 德國IDA Lab公司前來參觀洽商
IDA Lab visits for business talks



▲ 神經元入選Innovation World Cup官方競賽12強
Neurobit selected as a Top 12 Health Techpreneurs at the Innovation World Cup





▲ 博唯弘展產品介紹展板 Posters of Proview-MBD

博唯弘展生技成立於 2013 年，專精於水凝膠醫療器材之研發與製造，具備深厚的配方優化與創新研發實力。本公司依循嚴謹的品質管理系統與 ISO 13485 國際標準，生產涵蓋 第一至第三類(Class I-III)醫療器材產品。同時，公司亦具備完善的法規事務專業能力，全面符合 TFDA 法規要求。以術後防沾黏應用為核心發展領域，提供橫跨產品研發、法規驗證、量產製造至臨床應用之全生命週期高品質解決方案。

Founded in 2013, Proview-MBD Biotech specializes in the development and manufacturing of hydrogel-based medical devices, with strong R&D capabilities focused on formulation optimization and innovation. We produce Class I-III medical devices under strict QMS and ISO 13485 standards. Our expertise extends to regulatory affairs, ensuring full TFDA compliance. With a focus on post-surgical adhesion prevention, we deliver high-quality solutions across the entire product lifecycle.



▲ 博唯弘展入選台灣館趨勢發表會
Proview-MBD selected for Taiwan Pavilion Trend Presentation



網站
Website

聯絡人 Erica Ku
Contact ericaku@proview-biotech.com.tw

業務領域

Major Fields


- 專注於高效能水凝膠技術，應用於術後防沾黏屏障、關節滑液補充及醫療潤滑等臨床需求。
- Focused on high-performance hydrogels for post-surgical adhesion barriers, synovial fluid supplement, and medical lubrication.

合作意向

Business Interests

誠徵各國通路經銷夥伴，洽談直接出口與市場進入合作；同時開放具策略性之投資夥伴參與商品化、全球市場拓展及法規布局合作。

Seeking distribution partners for direct export and market entry collaboration. Open to strategic investors for commercialization, global expansion, and regulatory support.



▲博唯弘展團隊於攤位合照 Proview-MBD Team



▲展品照片 Product on display at the exhibition

產品介紹

Product Description

ThergiSpray 術後防沾黏噴霧型水凝膠

ThergiSpray 為單次劑量、液態、具溫感特性之術後防沾黏水凝膠噴霧，可有效改善目前市售防沾黏產品之使用限制與臨床不便性。產品適用於傳統開腹手術與微創手術，具備成本低、無需繁瑣前置準備、組裝快速、操作簡便等多項臨床優勢。本產品採用化學改質高分子之專利平台技術，可依臨床需求以凝膠或噴霧方式施作，為醫療專業人員與病患提供兼具便利性與經濟效益的術後防沾黏解決方案。

ThergiSpray



Thergispray is a single-dose, liquid-based, thermosensitive sprayable post-surgical anti-adhesion hydrogel that effectively solves the issues associated with existing products on the market. This product is suitable for both conventional and minimally invasive surgeries, and offers advantages including low cost, no time-consuming preparation, and easy assembly and use. The product utilizes a patented platform technology of chemically-modified polymers and can be applied as either a gel or spray, providing medical professionals and patients with a convenient and economical option.

AtamaBarrier Anti-Adhesion Gel 術後防沾黏凝膠

AtamaBarrier 防沾黏凝膠為高黏稠度、無致熱原之醫療級凝膠，可於硬脊膜外腔形成暫時性物理屏障。適用於腰椎椎板切除術、椎板開窗術或椎間盤切除術後，用以預防術後硬脊膜外沾黏之發生。透過降低纖維組織增生，可有效緩解術後疼痛、降低神經根病變風險，並促進下肢功能恢復，為脊椎手術後之臨床照護提供安全且具實證基礎的防沾黏解決方案。

AtamaBarrier Anti-Adhesion Gel

AtamaBarrier Anti-Adhesion Gel is a viscous and pyrogen-free gel designed to form a temporary physical barrier in the epidural space. It is intended for use after lumbar laminectomy, laminotomy, or discectomy to prevent postoperative epidural adhesions. By reducing fibrous tissue formation, AtamaBarrier helps relieve postoperative pain, decrease the risk of radiculopathy, and improve lower limb function recovery.



▲ 向參觀者介紹產品解決方案 Introducing product solutions



結語


近年來，愈來愈多臺北生技企業站上國際舞台，與全球醫療與生技產業建立實質連結，從市場接軌、品牌曝光到商務合作，皆展現出可被世界看見的能量。這些轉變不僅反映企業自身的成長，也象徵臺北生技產業正逐步融入全球供應鏈與創新網絡，為城市累積更深厚的國際競爭力。

臺北市政府自2018年起，即持續協助企業參與重要國際生技醫療展會，累積國際動能，並於2024年進一步推動「生技產業國際商機拓展計畫」，全面提升資源整合層級。連續兩年以全球規模最大、歷史最悠久的醫療器材專業展——德國杜塞道夫國際醫療器材展（MEDICA）為參展標的，攜手本市具代表性的生技醫療與醫材企業籌組「臺北展區」，累計參展企業達12家次，促成商務洽談超過700場，使國際買主、通路商與投資夥伴能在同一平台上，快速認識臺北的技術實力與合作潛力。

為了讓企業不只是「參展」，更能提升參展效益、深化商務洽談成果，並促成長期穩定的國際合作關係，市府在每一次國際參會出展前，皆提供一套完整的支持系統。從展前需求盤點、行前說明會到實務導向的輔導工作坊，協助企業在行銷策略、品牌定位、通路開發與市場分析等面向加速到位，降低企業出海風險，也讓更多中小型創新團隊有機會被世界看見。

在展會現場之外，亦同步整合MEDICA大會、外貿協會、生產力中心等多方資源，結合企業自有行銷能量，透過線上與線下並行的多元管道，持續放大品牌與產品的國際能見度。透過合作夥伴的引薦與串聯，協助企業對接國外法規諮詢、市場分析、補助計畫、資金媒合、歐盟市場導入以及數位健康跨域合作資源，不僅為企業爭取國際市場的入場券，也為臺北引入更多跨國合作與投資契機。

展望未來，臺北市政府將持續站在產業最需要的位置，深化與全球生技生態系的鏈結，透過更多元的國際參展平台、實質交流機會與產業政策支持，陪伴企業一步步走向更寬廣的世界舞台。當企業的創新被國際市場肯定，投資與合作持續回流，城市的就業、產值與產業能量也將同步成長；臺北不僅將穩健鞏固其作為亞太生技創新重鎮的角色，更將以全民共享的方式，全面展現「生技之都」的實力與影響力。



Conclusion

In recent years, a growing number of Taipei-based biotech companies have entered the global arena, forging tangible connections with the international medical and life-sciences sector. From market access and brand visibility to commercial partnerships, their competitiveness is increasingly recognised worldwide. This progress reflects not only corporate growth, but also Taipei’s gradual integration into global supply chains and innovation networks, strengthening the city’s long-term international competitiveness.

Since 2018, the Taipei City Government has continuously supported local companies in participating in major international biotech and medical exhibitions, building overseas momentum. In 2024, the city further launched the International Market Expansion Program for the Biotech Industry to strengthen resource integration. For two consecutive years, Taipei has targeted the world’s largest and longest-established medical trade fair—the MEDICA in Germany—organizing a “Taipei Pavilion” with representative local biotech and medical device firms. A total of 12 company participations have generated more than 700 business matchmaking meetings, enabling international buyers, distributors and investors to rapidly assess Taipei’s technological strengths and partnership potential.

To ensure that companies gain real commercial value from participation, rather than simply “exhibiting,” the city provides a comprehensive pre-exhibition support system. This includes needs assessments, briefing sessions and hands-on training workshops, helping firms strengthen marketing strategies, brand positioning, channel development and market analysis. These measures reduce the risks of overseas expansion and create greater exposure opportunities for small and mid-sized innovation teams.

Beyond the exhibition floor, the city also integrates resources from the MEDICA organizer, the Taiwan External Trade Development Council and the China Productivity Center, together with companies’ own marketing efforts. Through coordinated online and offline promotion, Taipei continues to enhance international brand visibility. Partner networks further assist companies in connecting with overseas regulatory advisory services, market intelligence, subsidies, investment matchmaking, EU market entry and cross-domain digital health collaborations—securing gateways to global markets while attracting multinational partnerships and investment into Taipei.

Looking ahead, the Taipei City Government will continue to deepen its links with the global biotech ecosystem through diversified exhibition platforms, substantive exchanges and sustained policy support. As innovation gains international recognition and investment and cooperation continue to flow back, the city’s employment, output and industrial capacity will grow in step—further consolidating Taipei’s role as a leading Asia-Pacific biotech innovation hub and fully showcasing its strength as a true “Biotech Capital.”

指導單位
Supervised



臺北市政府
Taipei City Government

主辦單位
Organized



TAIPEI
臺北市政府產業發展局
Department of Economic Development, Taipei City Government

執行單位
Executed



中國生產力中心
China Productivity Center

